Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
HP Version - Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
RecruitingLast updated: 2 February 2024
Clinical summaryEligibiltyParticipating hospitalsSupport
Eligible participants will receive treatment in two parts. In Part A, participants will undergo a biopsy, followed by one cycle (28 days) of treatment with AB-218, an orally available, small molecule inhibitor of mutated IDH1, and then a safe maximal resection (surgery) of the tumour. In Part B, following recovery from surgery, participants will receive up to 12 cycles of AB-218.
This trial is treating patients with IDH1 mutated Low Grade Glioma.
Brain and Spinal
18 - 40
AB218 gloma (Anheart)
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
Brain and spinal cord
Share with email
Print this page
Routine trial inclusion criteria
Patients who meet any of the following criteria will be excluded from participation in the study:
Routine trial exclusion criteria
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
Tell us if you find this trial availability is not accurate.Report inaccuracy
Speak with someone who has cancer clinical trial experience.
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.